CIK 0001855175 · Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
Contineum Therapeutics, Inc.
Sign in to watch- Ticker
- CTNM
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 271467257
- Phone
- (858) 333-5280
- Business address
- 3565 GENERAL ATOMICS COURT, SUITE 200, SAN DIEGO, CA, 92121
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $41,142
- in 1 filing, $41K under 10b5-1 plans
Net −$41,142. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-09-08 | Stengone Carmine N. CEO and President | Option exercise 10b5-1 | +2,500 | $1.01 | $3K | 19,717 |
| 2026-09-08 | Stengone Carmine N. CEO and President | Sale 10b5-1 | −2,500 | $16.46 | $41K | 17,217 |
| 2026-09-08 | Stengone Carmine N. CEO and President | Option exercise · Stock Option (right to buy) 10b5-1 | −2,500 | 274,430 | ||
| 2026-08-03 | Stengone Carmine N. CEO and President | Option exercise 10b5-1 | +2,500 | $1.01 | $3K | 19,717 |
| 2026-08-03 | Stengone Carmine N. CEO and President | Sale 10b5-1 | −2,500 | $16.01 | $40K | 17,217 |
| 2026-08-03 | Stengone Carmine N. CEO and President | Option exercise · Stock Option (right to buy) 10b5-1 | −2,500 | 276,930 | ||
| 2026-07-09 | Lorrain Daniel S. Chief Scientific Officer | Option exercise 10b5-1 | +25 | $1.01 | $25 | 135,227 |
| 2026-07-09 | Lorrain Daniel S. Chief Scientific Officer | Sale 10b5-1 | −25 | $16.00 | $400 | 135,202 |
| 2026-07-09 | Lorrain Daniel S. Chief Scientific Officer | Option exercise · Stock Option (right to buy) 10b5-1 | −25 | 33,257 | ||
| 2026-07-08 | Lorrain Daniel S. Chief Scientific Officer | Option exercise 10b5-1 | +1,015 | $1.01 | $1K | 136,217 |
| 2026-07-08 | Lorrain Daniel S. Chief Scientific Officer | Sale 10b5-1 | −1,015 | $16.00 | $16K | 135,202 |
| 2026-07-08 | Lorrain Daniel S. Chief Scientific Officer | Option exercise · Stock Option (right to buy) 10b5-1 | −1,015 | 33,282 | ||
| 2026-07-08 | Stengone Carmine N. CEO and President | Option exercise 10b5-1 | +2,500 | $1.01 | $3K | 19,717 |
| 2026-07-08 | Stengone Carmine N. CEO and President | Sale 10b5-1 | −2,500 | $16.00 | $40K | 17,217 |
| 2026-07-08 | Stengone Carmine N. CEO and President | Option exercise · Stock Option (right to buy) 10b5-1 | −2,500 | 279,430 | ||
| 2026-07-01 | Lorrain Daniel S. Chief Scientific Officer | Option exercise 10b5-1 | +4,183 | $1.01 | $4K | 143,555 |
| 2026-07-01 | Lorrain Daniel S. Chief Scientific Officer | Sale 10b5-1 | −5,852 | $15.67 | $92K | 137,703 |
| 2026-07-01 | Lorrain Daniel S. Chief Scientific Officer | Sale 10b5-1 | −2,501 | $16.24 | $41K | 135,202 |
| 2026-07-01 | Lorrain Daniel S. Chief Scientific Officer | Option exercise · Stock Option (right to buy) 10b5-1 | −4,183 | 34,297 | ||
| 2026-06-30 | Lorrain Daniel S. Chief Scientific Officer | Option exercise 10b5-1 | +28,826 | $1.01 | $29K | 168,198 |
Page 1 of 7 · 139 trades